HomeBUSINESS
BUSINESS

Otsuka Ventures into Antibody Space with Visterra Buyout
(Jul.12.2018)

Otsuka Pharmaceutical is acquiring MIT spinout Visterra in a US$430 million cash deal, marking its foray into the antibody arena, the Japanese company said on July 11. The transaction is slated to close by the end of September ...
(LOG IN FOR FULL STORY)

News Calendar